Eight Biopharmaceuticals
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
343 Thornall St Ste 520, Edison, New Jer...Phone Number
(848) 300-0086Website
www.7and8biopharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Eight Biopharmaceuticals
Seven and Eight Biopharmaceuticals Inc. is an experienced biopharmaceutical company committed to discovering and developing new and innovative immunotherapies. Researchers and Clinicians at Seven and Eight Biopharma are using advanced techniques to develop novel therapies to activate the immune system against cancer. Ongoing clinical trials are studying these novel therapies in patients with cancer.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Eight Biopharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Eight Biopharmaceuticals
Funding: Get notified immidiatlly once Eight Biopharmaceuticals has new funding data
Earning: See what the market has to say on Eight Biopharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Eight Biopharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if Eight Biopharmaceuticals is spiking on competitors!
Eight Biopharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Eight Biopharmaceuticals launches new products
Click to see if Eight Biopharmaceuticals had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Eight Biopharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Eight Biopharmaceuticals
Compare insights from companies similar to Eight Biopharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Eight Biopharmaceuticals
<$5M
11-50
Private
-
2017
N/A
Company Profile Activity
Activity Insights
Eight Biopharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Eight Biopharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Eight Biopharmaceuticals.
Eight Biopharmaceuticals Tech Stack
A closer look at the technologies used by Eight Biopharmaceuticals
See more technologies
Eight Biopharmaceuticals News & Media
Seven and Eight Biopharma’s BDB001 in Combination with an anti-PD-L1 mAb Shows Favorable Safety and Clinical Responses in Interim Phase 1 Data Presented at the 2021 SITC Annual Meeting
EDISON, N.J.--(BUSINESS WIRE)--Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, announces the presentation of interim Phase 1 data for BDB001 in combination with atezolizumab in advanced solid tumors at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting. BDB001 is an immune modulator capable of activating dendritic cells to initiate both innate andSeven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a Phase 2 Clinical Trial of the TLR 7/8 dual agonist BDB001 in anti-PD-1 / anti-PD-L1 Refractory Solid Tumors
EDISON, N.J.--(BUSINESS WIRE)--Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, announced today that the first patient has been treated in a Phase 2 clinical trial evaluating BDB001 in advanced solid tumors at The University of Texas MD Anderson Cancer Center in Houston, TX. BDB001 is an intravenously administered Toll-Like Receptor 7 and 8 (TLR 7/8) duaSeven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a First-in-Human Clinical Trial of the TLR7/8 dual agonist BDB018 in Advanced Solid Tumors
EDISON, N.J.--(BUSINESS WIRE)--Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, announced today that the first patient was treated in a First-in-Human Phase 1 clinical trial evaluating BDB018 in advanced solid tumors at Florida Cancer Specialists & Research Institute in Sarasota, FL. BDB018 is a next-generation intravenously administered Toll-Like ReSeven and Eight Biopharma’s BDB001 in Combination with Pembrolizumab Shows Favorable Safety and Clinical Responses in Interim Phase 1 Data Presented at the 2021 ASCO Annual Meeting
EDISON, N.J.--(BUSINESS WIRE)--Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, announces the presentation of Phase 1 data for BDB001 in combination with pembrolizumab in advanced solid tumors at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. BDB001 is an immune modulator capable of activating dendritic cells to initiate both innate and adapt
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Eight Biopharmaceuticals
Sign Up For FreeTo access detailed company insights
Seven and Eight Biopharmaceuticals Inc. is an experienced biopharmaceutical company committed to discovering and developing new and innovative immunotherapies. Researchers and Clinicians at Seven and Eight Biopharma are using advanced techniques to develop novel therapies to activate the immune system against cancer. Ongoing clinical trials are stu... Read More
